Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
ALNY Key Statistics
Stock Snapshot
As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $440.49. The company's market cap stands at 58.19B, with a P/E ratio of 1807.65.
As of 2025-11-06, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $429.00 and $445.49. The current price stands at $440.49, placing the stock +2.7% above today's low and -1.1% off the high.
The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 693.55K, compared to an average daily volume of 1.27M.
In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.
In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.
ALNY News
Wondering if Alnylam Pharmaceuticals is actually good value right now? You are not alone, especially with all the hype and debate around biotech stocks lately....
Goldman Sachs analysts removed Alnylam (ALNY) from the firm’s US Conviction List as part of its monthly update. Elevate Your Investing Strategy: Take advantag...
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface...
Analyst ratings
72%
of 32 ratingsMore ALNY News
Alnylam Pharmaceuticals (ALNY) achieved profitability over the past year, with average annual earnings growth of 27.5% over the last five years. Looking ahead,...
Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...
Alnylam Pharmaceuticals ( (ALNY) ) has released its Q3 earnings. Here is a breakdown of the information Alnylam Pharmaceuticals presented to its investors. Elev...